Research at Oslo University Hospital basis for international drug development initiative between Norway and India
Kjetil Taskén (left) and Ivar Sjaastad
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.
The work has involved Birgitte Lygren (former postdoc), Ellen Østensen (PhD 2016), Ana Calejo (former postdoc and now researcher with UiO SPARK grant) in the Taskén group at UiO/OUH and has been done in collaboration with Professor Jo Klaveness at Institute of Pharmacy and Professor Ivar Sjaastad and Researcher Jan Magnus Aaronsen at Institute of Experimental Medical Research at Oslo University Hospital and in collaboration with Inven2, particularly Mohammed Amarzguioui and Kristin Sandereid, that have been involved in the technology and business development and led to the establishment of SERCA Pharmaceuticals AS.
SERCA Pharmaceuticals AS has won a 5-mill NOK Forny grant from RCN. The agreement with Cadila will take the project forward and provides a real chance to go into humans with planned phase 1 and 2 studies.
Inven2's most recent startup company, Serca Pharmaceuticals, signed a development agreement with Cadila Pharmaceuticals in New Delhi today. The signing was overseen by Prime Minister of Norway, Erna Solberg, during her official visit to India. Serca Pharmaceuticals is based on breakthrough science from Kjetil Taskéns Group at the University of Oslo. Read more
From major journals, first or last author from the Institute for Cancer Research
Eggebø MS, Heinzelbecker J, Palashati H, Chandler N, Tran TT, Li Y, Yang W, Laos M, Blaas I, Rustad EH, Bollineni RC, Delic-Sarac M, Lund-Johansen F, Nielsen MM, Olweus J(2025) TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors Nat Immunol(in press) DOI 10.1038/s41590-025-02252-1, PubMed 40866620
Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA(2025) Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy Mol Oncol(in press) DOI 10.1002/1878-0261.70117, PubMed 40852937
Foldvari Z, Brennan MS, Titov A, Jacobsen SEW, Olweus J(2025) Targeting the roots of myeloid malignancies with T cell receptors Nat Rev Cancer(in press) DOI 10.1038/s41568-025-00857-0, PubMed 40841587
Nie X, Sun Y, van Dijk DPJ, Deng M, Brecheisen R, Wang Z, Xia Q, Olde Damink SMW, Rensen SS(2025) Loss of Skeletal Muscle Mass Is Associated With Reduced Cytotoxic T Cell Abundance and Poor Survival in Advanced Lung Cancer J Cachexia Sarcopenia Muscle, 16(5), e70063 DOI 10.1002/jcsm.70063, PubMed 40931431
Ølnes ÅS, Teigen M, Laerdahl JK, Leren TP, Strøm TB, Bjune K(2025) Correction: Variants in the CETP gene affect levels of HDL cholesterol by reducing the amount, and not the specific lipid transfer activity, of secreted CETP PLoS One, 20(9), e0332400 DOI 10.1371/journal.pone.0332400, PubMed 40938802
Presacan O, Hernández Mesa M, Aldea AC, Andresen S, Al Outa A, Aarmo Johannessen J, Ionescu B, Knævelsrud H, Riegler MA(2025) Explainable AI to unveil cellular autophagy dynamics PLoS One, 20(9), e0331045 DOI 10.1371/journal.pone.0331045, PubMed 40934250